Germany · Delayed Price · Currency is EUR Episurf Medical AB Statistics
Total Valuation
FRA:16E has a market cap or net worth of EUR 4.37 million. The enterprise value is 2.91 million.
| Market Cap | 4.37M |
| Enterprise Value | 2.91M |
Important Dates
The next estimated earnings date is Friday, February 6, 2026.
| Earnings Date | Feb 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.66B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +95.30% |
| Shares Change (QoQ) | +61.86% |
| Owned by Insiders (%) | 7.68% |
| Owned by Institutions (%) | 13.07% |
| Float | 1.16B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.26 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.51 |
| EV / Sales | 1.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.75 |
| Quick Ratio | 2.27 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -89.71 |
Financial Efficiency
Return on equity (ROE) is -76.91% and return on invested capital (ROIC) is -45.61%.
| Return on Equity (ROE) | -76.91% |
| Return on Assets (ROA) | -41.29% |
| Return on Invested Capital (ROIC) | -45.61% |
| Return on Capital Employed (ROCE) | -97.67% |
| Revenue Per Employee | 74,448 |
| Profits Per Employee | -218,474 |
| Employee Count | 27 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 16.12 |
Taxes
In the past 12 months, FRA:16E has paid 45,225 in taxes.
| Income Tax | 45,225 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.45% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -95.45% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 47.71 |
| Average Volume (20 Days) | 6,343 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:16E had revenue of EUR 1.94 million and -5.68 million in losses. Loss per share was -0.01.
| Revenue | 1.94M |
| Gross Profit | -2.80M |
| Operating Income | -5.68M |
| Pretax Income | -5.64M |
| Net Income | -5.68M |
| EBITDA | -5.62M |
| EBIT | -5.68M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.96 million in cash and 515,570 in debt, giving a net cash position of 1.45 million.
| Cash & Cash Equivalents | 1.96M |
| Total Debt | 515,570 |
| Net Cash | 1.45M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.59M |
| Book Value Per Share | 0.00 |
| Working Capital | 1.94M |
Cash Flow
| Operating Cash Flow | -5.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -144.86%, with operating and profit margins of -293.46% and -293.46%.
| Gross Margin | -144.86% |
| Operating Margin | -293.46% |
| Pretax Margin | -291.12% |
| Profit Margin | -293.46% |
| EBITDA Margin | -290.19% |
| EBIT Margin | -293.46% |
| FCF Margin | n/a |
Dividends & Yields
FRA:16E does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -95.30% |
| Shareholder Yield | -95.30% |
| Earnings Yield | -129.99% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:16E has an Altman Z-Score of -13.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.79 |
| Piotroski F-Score | 3 |